JP5605895B2 - Ｃｏｐｄを処置するためのｃｄ２０結合分子 - Google Patents

Ｃｏｐｄを処置するためのｃｄ２０結合分子 Download PDF

Info

Publication number
JP5605895B2
JP5605895B2 JP2009516903A JP2009516903A JP5605895B2 JP 5605895 B2 JP5605895 B2 JP 5605895B2 JP 2009516903 A JP2009516903 A JP 2009516903A JP 2009516903 A JP2009516903 A JP 2009516903A JP 5605895 B2 JP5605895 B2 JP 5605895B2
Authority
JP
Japan
Prior art keywords
copd
amino acid
antibody
seq
chronic obstructive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009516903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009541374A5 (enExample
JP2009541374A (ja
Inventor
ポール パーレン
ステーン リスビー
オレ バッズガルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS filed Critical Genmab AS
Publication of JP2009541374A publication Critical patent/JP2009541374A/ja
Publication of JP2009541374A5 publication Critical patent/JP2009541374A5/ja
Application granted granted Critical
Publication of JP5605895B2 publication Critical patent/JP5605895B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2009516903A 2006-07-04 2007-07-04 Ｃｏｐｄを処置するためのｃｄ２０結合分子 Active JP5605895B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200600916 2006-07-04
DKPA200600916 2006-07-04
US81859306P 2006-07-05 2006-07-05
US60/818,593 2006-07-05
PCT/DK2007/000339 WO2008003319A1 (en) 2006-07-04 2007-07-04 Cd20 binding molecules for the treatment of copd

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014109829A Division JP2014208651A (ja) 2006-07-04 2014-05-28 Ｃｏｐｄを処置するためのｃｄ２０結合分子

Publications (3)

Publication Number Publication Date
JP2009541374A JP2009541374A (ja) 2009-11-26
JP2009541374A5 JP2009541374A5 (enExample) 2010-08-26
JP5605895B2 true JP5605895B2 (ja) 2014-10-15

Family

ID=47390906

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009516903A Active JP5605895B2 (ja) 2006-07-04 2007-07-04 Ｃｏｐｄを処置するためのｃｄ２０結合分子
JP2014109829A Withdrawn JP2014208651A (ja) 2006-07-04 2014-05-28 Ｃｏｐｄを処置するためのｃｄ２０結合分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014109829A Withdrawn JP2014208651A (ja) 2006-07-04 2014-05-28 Ｃｏｐｄを処置するためのｃｄ２０結合分子

Country Status (5)

Country Link
US (1) US20130004480A1 (enExample)
EP (1) EP2046383B1 (enExample)
JP (2) JP5605895B2 (enExample)
CA (1) CA2656620C (enExample)
WO (1) WO2008003319A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
RU2386438C1 (ru) * 2008-12-04 2010-04-20 Государственное Образовательное Учреждение Высшего Профессионального Образования Амурская Государственная Медицинская Академия Росздрава Способ комплексного лечения хронической обструктивной болезни легких в стадии ремиссии
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
JP5933573B2 (ja) 2010-11-08 2016-06-15 ノバルティス アーゲー Ｃｘｃｒ２結合ポリペプチド
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2016168565A1 (en) * 2015-04-16 2016-10-20 President And Fellows Of Harvard College Methods for treatment of chronic obstructive pulmonary disease and/or therapy monitoring
US20180096104A1 (en) * 2016-10-05 2018-04-05 MED Inc. Disease management system
CA3046489A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CN108395482B (zh) * 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
AU2024244733B2 (en) 2023-03-31 2025-12-11 AbelZeta Inc. Bispecific chimeric antigen receptors targeting cd20 and bcma

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
WO2002012437A2 (en) 2000-08-03 2002-02-14 Schooten Wim Van Production of humanized antibodies in transgenic animals
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
JP4298498B2 (ja) 2001-06-13 2009-07-22 ゲンマブ エー／エス 上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
AU2002367427A1 (en) * 2001-12-28 2003-07-24 Takeda Chemical Industries, Ltd. Biaryl compound and use thereof
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
PL216630B1 (pl) 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
NZ540555A (en) 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
ES2373947T3 (es) 2002-12-16 2012-02-10 Genmab A/S Anticuerpos monoclonales humanos contra interleucina 8 (il-8).
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
GB0324888D0 (en) * 2003-10-24 2003-11-26 Novartis Ag Organic compounds
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
JP2008504363A (ja) * 2004-06-29 2008-02-14 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｐ２ｘ７受容体のベンズアミド阻害剤を利用する併用療法
EP3312196B1 (en) 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
AU2006317242A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof

Also Published As

Publication number Publication date
JP2014208651A (ja) 2014-11-06
US20130004480A1 (en) 2013-01-03
WO2008003319A1 (en) 2008-01-10
EP2046383B1 (en) 2014-11-19
EP2046383A1 (en) 2009-04-15
CA2656620C (en) 2018-03-13
CA2656620A1 (en) 2008-01-10
JP2009541374A (ja) 2009-11-26

Similar Documents

Publication Publication Date Title
JP5605895B2 (ja) Ｃｏｐｄを処置するためのｃｄ２０結合分子
JP7609901B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
EP3703818B1 (en) Il-4r antagonist for use in a method for treating or preventing asthma
JP2009541374A5 (enExample)
JP2012515217A (ja) ベンダムスチンおよび抗−ｃｄ２０抗体の組合せを用いた癌治療
CN111655290A (zh) 抗组织因子抗体-药物偶联物及其在癌症治疗中的应用
TW202027783A (zh) 用於癌症之組合療法
RU2749951C2 (ru) Схемы и способы лечения рассеянного склероза с применением офатумумаба
US20210347889A1 (en) Dosing regimen of anti-lag3 antibody and combination therapy with anti-pd-1 antibody for treating cancer
US20050089517A1 (en) Treatment of respiratory diseases with anti-IL-2 receptor antibodies
US12552869B2 (en) CSF-1R antibodies for the treatment of chronic graft versus host disease
JP2022549218A (ja) 抗トリプターゼ抗体の投薬
AU2018263159A1 (en) Methods of selectively treating asthma using IL-17 antagonists
JP7216157B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
US20250333499A1 (en) Bispecific antibodies and methods of using the same
RU2801531C2 (ru) Способы лечения или предотвращения астмы посредством введения антагониста il-4r
TW202544036A (zh) 用抗ｔｓｌｐ抗體治療慢性阻塞性肺病
EP4647084A1 (en) Method for treating asthma by using tslp antibody
CN116490520A (zh) 用于covid-19肺炎的托珠单抗和瑞德西韦组合疗法
CN117940452A (zh) 用于治疗癌症的方法和组合物
CN115916820A (zh) 用il6拮抗剂治疗包括covid-19肺炎在内的肺炎的方法
EA048942B1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
NZ619873B2 (en) Methods and compositions for treating asthma using anti-il-13 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121001

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130311

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130910

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140528

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140630

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140820

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140822

R150 Certificate of patent or registration of utility model

Ref document number: 5605895

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250